Search Results
Your search for ,foR matches 32412 pages
Showing 10551 - 10600Novel Indications and New Drugs for the Treatment of Patients With Breast Cancer
Over the past year (December 2019–September 2020), the U.S. Food and Drug Administration (FDA) granted approval to several novel drugs and new indications for therapeutic agents used in breast cancer. Pertuzumab/Trastuzumab/Hyaluronidase-zzxf On June 29, 2020, the FDA approved a new fixed-dose...
Emerging Alternatives in the Third-Line Setting for Metastatic HER2-Positive Breast Cancer
In the post-trastuzumab era, a number of U.S. Food and Drug Administration (FDA)-approved targeted agents for metastatic HER2-positive breast cancer are available, but there is no preferred option for third-line treatment and beyond. At the 2019 Chemotherapy Foundation Symposium, Shanu Modi, MD,...
Tucatinib Combination in Previously Treated HER2-Positive Metastatic Breast Cancer With Brain Metastases
In an analysis of the pivotal phase III HER2CLIMB trial reported at the ASCO20 Virtual Scientific Program, Nancy U. Lin, MD, of Dana-Farber Cancer Institute, Boston, and colleagues found that tucatinib, a small-molecule tyrosine kinase inhibitor that is highly selective for HER2, plus...
First-Line Atezolizumab vs Chemotherapy in PD-L1–Positive Metastatic NSCLC: IMpower110
As reported in The New England Journal of Medicine by Roy S. Herbst, MD, PhD, and colleagues, the phase III IMpower110 trial has shown significantly prolonged overall survival with first-line atezolizumab vs platinum-based chemotherapy in patients with metastatic non–small cell lung cancer (NSCLC)...
Local Recurrence With Radiation Boost in HER2-Positive Breast Cancer: HERA Trial Analysis
In a retrospective analysis reported in the International Journal of Radiation Oncology • Biology • Physics, Joseph Abi Jaoude, MD, of the American University of Beirut Medical Center, and colleagues found that a radiation boost did not reduce the risk of local recurrence among women with...
Advanced HER2-Positive Breast Cancer: All Eyes on These Novel Agents
New agents for the treatment of advanced HER2-positive breast cancer should be coming soon to your clinic, according to Sara A. Hurvitz, MD, Director of the Breast Cancer Clinical Research Program and Associate Professor of Medicine at the David Geffen School of Medicine at the University of...
Updates From Additional Clinical Trials in HER2-Positive Breast Cancer
Here we present summaries of several additional clinical trials in HER2-positive breast cancer reported over the past year. Jame Abraham, MD, Chair of the Division of Hematology and Oncology at the Taussig Cancer Center, Cleveland Clinic, shared his perspective on several of these trials presented ...
Expert Point of View: Ian E. Krop, MD, PhD, Angela M. DeMichele, MD, MSCE, and Carlos L. Arteaga, MD
Ian E. Krop, MD, PhD, of Dana-Farber Cancer Institute, Boston, said that margetuximab is one of three new “exciting” drugs in the HER2-positive setting with different mechanisms of action; the other two are tucatinib and trastuzumab deruxtecan. “Margetuximab is a modified version of trastuzumab...
Phase III SOPHIA Trial Evaluates Margetuximab/Chemotherapy vs Trastuzumab/Chemotherapy for HER2-Positive Breast Cancer
The second interim analysis of the phase III SOPHIA trial demonstrated a significant, though modest, improvement in progression-free survival, response rate, and clinical benefit with the addition of margetuximab to chemotherapy vs trastuzumab plus chemotherapy in patients with HER2-positive...
Abemaciclib/Fulvestrant/Trastuzumab for Patients With Previously Treated HR-Positive, HER2-Positive Advanced Breast Cancer
In the phase II monarcHER trial reported in The Lancet Oncology, Sara M. Tolaney, MD, of Dana-Farber Cancer Institute, Boston, and colleagues, found that the combination of abemaciclib, fulvestrant, and trastuzumab prolonged progression-free survival vs trastuzumab plus standard-of-care...
Neratinib in Previously TreatedHER2-Positive Metastatic Breast Cancer: Point of View From the NALA Trial
Neratinib is an oral pan-HER tyrosine kinase inhibitor that is approved by the U.S. Food and Drug Administration (FDA) for two indications. The first is as adjuvant treatment of early-stage HER2-positive breast cancer following adjuvant trastuzumab therapy. The second is in combination with...
2020 Nobel Prize in Physiology or Medicine Awarded to Team Who Discovered Hepatitis C Virus
This year’s Nobel Prize in Physiology or Medicine was awarded to three scientists who have made a decisive contribution to the fight against blood-borne hepatitis, a major global health problem that causes cirrhosis and liver cancer in people around the world. Harvey J. Alter, MD; Michael Houghton, ...
Four-Year Findings From the MURANO Trial: Venetoclax Plus Rituximab for Relapsed Chronic Lymphocytic Leukemia
As reported in the Journal of Clinical Oncology by Kater et al, 4-year progression-free and overall survival were significantly greater with venetoclax plus rituximab vs bendamustine plus rituximab in the phase III MURANO trial in patients with relapsed or refractory chronic lymphocytic leukemia....
Patient Experiences of Acute Toxicity From Breast Radiotherapy According to Fractionation Scheme
In a study reported in the Journal of Clinical Oncology, Reshma Jagsi, MD, DPhil, and colleagues found differences in patient reports of acute toxicities according to fractionation scheme of whole-breast radiotherapy for breast cancer, with pain being reported more frequently in Black vs White...
Pilot Study Finds Liquid Biopsy Delivers Results Faster Than Tissue Biopsy
A pilot study comparing liquid biopsy with tissue-based testing showed that liquid biopsy delivered results approximately 10 days faster than tissue biopsy, according to research presented by Nir Peled, MD, PhD, and colleagues at the International Association for the Study of Lung Cancer (IASLC)...
Liquid Biopsy May Be a Timely and Effective Testing Method for Patients With NSCLC: Findings From Canada
Next-generation sequencing of cell-free DNA (cfDNA) obtained from blood samples may improve diagnostic testing in patients with advanced non–small cell lung cancer (NSCLC) and may also be faster and less expensive than standard tissue profiling, according to research presented by Natasha B. Leighl, ...
FDA Approves Nivolumab Plus Ipilimumab for the First-Line Treatment of Unresectable Malignant Pleural Mesothelioma
On October 2, the U.S. Food and Drug Administration (FDA) approved the combination of nivolumab (Opdivo) plus ipilimumab (Yervoy) as first-line treatment for adult patients with unresectable malignant pleural mesothelioma. CheckMate 743 Efficacy was investigated in CheckMate 743, a randomized,...
Jeffrey S. Weber, MD, PhD, on Melanoma: Adjuvant Nivolumab vs Ipilimumab
Jeffrey S. Weber, MD, PhD, of the Perlmutter Cancer Center, NYU Langone, discusses the 4-year recurrence-free and overall survival results from the CheckMate 238 study, which showed adjuvant nivolumab continues to be an effective treatment, vs the comparator ipilimumab, for patients with resected...
Expert Point of View: Lisa A. Carey, MD
Invited study discussant Lisa A. Carey, MD, the Richardson and Marilyn Jacobs Preyer Distinguished Professor in Breast Cancer Research and Deputy Director of Clinical Sciences at the University of North Carolina-Chapel Hill, framed her remarks as a tale of two trials. Dr. Carey asked these...
IMpassion131: No Benefit for Atezolizumab Plus Paclitaxel in Triple-Negative Breast Cancer
Based on some unexpected negative results, oncologists using atezolizumab for metastatic triple-negative breast cancer should pair it with nab-paclitaxel, not paclitaxel. In contrast to the overall survival benefit shown for atezolizumab plus nab-paclitaxel in the previous IMpassion130...
FDA Pipeline: Priority Review for Agents in Multiple Myeloma, Anaplastic Large Cell Lymphoma
Recently, the U.S. Food and Drug Administration (FDA) granted Priority Review to therapies for pretreated patients with multiple myeloma and pediatric patients with ALK-positive anaplastic large cell lymphoma; granted Fast Track designation to novel agents in gastric/gastroesophageal junction...
Adjuvant Trastuzumab With or Without Chemotherapy for Older Patients With HER2-Positive Early Breast Cancer
In the Japanese RESPECT trial reported in the Journal of Clinical Oncology, Sawaki et al found that noninferiority of adjuvant trastuzumab alone vs with chemotherapy was not shown for disease-free survival among women with HER2-positive breast cancer between the ages of 70 and 80 years. However, a...
Four-Year Outcomes in CheckMate 238: Adjuvant Nivolumab vs Ipilimumab in Stage IIIB–IIIC or IV Melanoma
As reported in The Lancet Oncology by Paolo A. Ascierto, MD, and colleagues, 4-year results of the CheckMate 238 trial show the continued benefit of adjuvant nivolumab vs ipilimumab in recurrence-free and metastasis-free survival in patients with resected stage IIIB–IIIC or IV melanoma, with no...
Long-Term Outcomes With Neoadjuvant Therapy Followed by Surgery in Rectal Adenocarcinoma: Focus on Pathologic Response
For patients with rectal adenocarcinoma treated with neoadjuvant therapy followed by operative resection, “achieving a pathologic complete response is associated with excellent long-term disease-free and overall survival,” according to the results of a study reported by Naomi M. Sell, MD, MHS, of...
ASCO’s National Cancer Opinion Survey Reveals Concerns Over Delays in Cancer Screenings Due to COVID-19 and Inequities in Health Care
Findings from ASCO’s fourth annual National Cancer Opinion Survey showed the toll the COVID-19 pandemic is taking on patients with cancer and the concerns over delays in scheduling cancer screenings. In addition, a majority of survey respondents acknowledged that racism can impact the care a person ...
Is Cancer Mortality Higher in Counties That Experience Persistent Poverty?
Residents of counties that experience persistent poverty face a disproportionately high risk of cancer mortality, according to a study published by Jennifer L. Moss, PhD, and colleagues in Cancer Epidemiology, Biomarkers & Prevention. Persistent Poverty Areas of persistent poverty are defined...
Long-Term Impact of ADT in Favorable vs Unfavorable Intermediate-Risk Prostate Cancer
In an analysis of long-term data from NRG Oncology’s RTOG 9408 trial reported in JAMA Network Open, Zumsteg et al found that patients with favorable vs unfavorable intermediate-risk prostate cancer had improved overall survival, and that androgen-deprivation therapy (ADT) vs no ADT was associated...
Novel Small-Molecule Inhibitor Surufatinib for Advanced Extrapancreatic Neuroendocrine Tumors
In the Chinese phase III SANET-ep trial reported in The Lancet Oncology, Xu et al found that surufatinib improved progression-free survival vs placebo in patients with advanced extrapancreatic neuroendocrine tumors. Surufatinib is a novel small-molecule inhibitor that targets VEGFR-1, VEGFR-2,...
First-Line Durvalumab With or Without Tremelimumab vs Chemotherapy for Metastatic Urothelial Carcinoma
In the phase III DANUBE trial, reported in The Lancet Oncology, Thomas Powles, MD, PhD, and colleagues found that durvalumab monotherapy did not prolong overall survival vs standard chemotherapy in previously untreated patients with largely metastatic urothelial carcinoma with high PD-L1...
Addition of Atezolizumab to Neoadjuvant Chemotherapy in Early-Stage Triple-Negative Breast Cancer: IMpassion031 Trial
As reported in The Lancet by Elizabeth A. Mittendorf, MD, and colleagues, results from the phase III IMpassion031 trial showed improved pathologic complete response rates with the addition of atezolizumab to sequential nab-paclitaxel and anthracycline-based neoadjuvant chemotherapy in patients with ...
Adjuvant Abemaciclib Plus Endocrine Therapy in Patients With Early Breast Cancer at High Risk of Recurrence: monarchE Trial
As reported in the Journal of Clinical Oncology by Stephen R.D. Johnston, MD, PhD, and colleagues, the phase III monarchE trial has shown that adjuvant abemaciclib plus endocrine therapy significantly improved invasive disease–free survival vs endocrine therapy alone in patients with hormone...
Ending Systemic Racism in Oncology Is Everyone’s Responsibility
Five years ago, as Rachel B. Issaka, MD, MAS, was beginning her second year as a gastroenterology fellow and feeling proud of the progress she was making in her training, she was suddenly confronted with an all-too-familiar slight that underrepresented minority providers may often experience. As...
Genetic Testing May Be Cost-Effective for Newly Diagnosed Patients With GIST
In a paper published by Banerjee et al in JAMA Network Open, researchers reported that genetic testing is cost-effective and beneficial for newly diagnosed patients with metastatic gastrointestinal stromal tumors (GIST), a type of soft-tissue sarcoma that develops in specialized nerve cells in the...
Activity of the KRAS G12C Inhibitor Sotorasib in KRAS p.G12C–Mutant Advanced Solid Tumors
As reported in The New England Journal of Medicine by David S. Hong, MD, and colleagues, the phase I CodeBreaK100 trial showed activity of the oral KRAS G12C inhibitor sotorasib in heavily pretreated patients with KRAS p.G12C–mutant advanced non–small cell lung cancer (NSCLC), colorectal cancer,...
Consolidation Radiotherapy for Patients With Advanced Hodgkin Lymphoma and a Large Nodal Mass
As reported in the Journal of Clinical Oncology by Gallamini et al, the final analysis of the phase III GITIL/FIL HD0607 trial has shown that consolidation radiotherapy did not improve progression-free survival vs no further treatment in patients with advanced Hodgkin lymphoma and a baseline large...
An MSK Hospitalist Looks at Oncologists’ Attitudes About Inpatient Cancer Care
Each year in the United States, about five million adults with cancer are admitted to hospitals. Given our aging population, this trend will increase, putting added stress on the oncology community, which is already dealing with an impending workforce shortage. Although physician extenders, such...
Monika K. Krzyzanowska, MD, MPH, on Early-Stage Breast Cancer: Ambulatory Toxicity Management in the AToM Study
Monika K. Krzyzanowska, MD, MPH, of the Princess Margaret University Health Network, discusses study findings on remote proactive telephone-based toxicity management for patients with breast cancer receiving chemotherapy. Although the telehealth program was associated with fewer grade 3 toxicities...
Lisa A. Carey, MD, on Triple-Negative Breast Cancer: Paclitaxel, Nab-paclitaxel, and Atezolizumab in IMpassion Trials
Lisa A. Carey, MD, of the University of North Carolina, discusses phase III results from two IMpassion trials, 130 and 131, which explored, respectively, atezolizumab plus nab-paclitaxel vs placebo plus nab-paclitaxel in previously untreated locally advanced or metastatic triple-negative breast...
First-in-Class Human IgG4 Monoclonal Antibody Shows Activity Alone and Combined With Pembrolizumab in Advanced Solid Tumors
MK-4830—a novel, first-in-class human IgG4 monoclonal antibody targeting the myeloid-specific anti–immunoglobulin-like transcript 4 (ILT4) receptor—administered either as a single agent or in combination with pembrolizumab was well tolerated and showed activity in heavily pretreated patients with...
Is ctDNA Effective in Detecting Genomic Alterations in Patients With Metastatic Kidney Cancer?
Circulating tumor DNA (ctDNA) analysis is a minimally invasive genomic assessment tool utilizing targeted next-generation sequencing of peripheral blood. At the ESMO Virtual Congress 2020, Zengin et al reported genomic results from a large cohort of patients with metastatic renal cell carcinoma...
Nonlymphoma Mortality Following Initial Chemotherapy in Patients With Classical Hodgkin Lymphoma
In a study reported in the Journal of Clinical Oncology, Dores et al found that patients with classical Hodgkin lymphoma continue to be at elevated risk for mortality from causes other than lymphoma, despite advances in treating this disease. As stated by the investigators, “Mortality for patients...
Addition of Immunotherapy to Other Treatments in Patients With Brain Metastases After Definitive Surgery
In a National Cancer Database analysis reported in JAMA Network Open, Amin et al found that among patients with brain metastases who underwent definitive surgery for primary tumors, the combination of immunotherapy and radiotherapy prolonged overall survival compared with radiotherapy alone. Study...
Benefit of Pembrolizumab in High-Risk Stage III Melanoma: 3-Year Follow-up
As reported in the Journal of Clinical Oncology by Alexander M.M. Eggermont, MD, PhD, and colleagues, adjuvant pembrolizumab maintained a significant recurrence-free survival benefit vs placebo in patients with high-risk stage III melanoma after a median 3-year follow-up in the phase III EORTC...
Alexander M. Eggermont, MD, PhD, on Melanoma: Pembrolizumab vs Placebo After Complete Resection
Alexander M. Eggermont, MD, PhD, of the Princess Maxima Center for Pediatric Oncology, discusses final results of the phase III EORTC 1325-MG/Keynote 054 trial, which confirmed a sustained recurrence-free survival benefit of pembrolizumab vs placebo in patients with resected high-risk stage III...
